Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 33Active not recruiting 23Completed 8Suspended 2Not yet recruiting 2Terminated 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 9Neoplasms 7Multiple Myeloma 7Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Lung Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Rectal Neoplasms 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Glioblastoma 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡